Mirxes Holding Company Limited, a micro ribonucleic acid technology company, provides diagnostic solutions for the screening of cancer, cardiovascular, metabolic, and infectious diseases accessible across Singapore and China. The company offers GASTROClear, a blood-based miRNA detection panel consisting of 12 miRNA biomarkers for gastric cancer screening; LUNGClear, a lung cancer screening product candidate; and Fortitude COVID-19 RT-qPCR test kits. It also researches, develops, and manufactures biotechnology, life, and medical science related products. The company was founded in 2014 and is headquartered in Singapore.
Frequently asked questions
What sector does Mirxes Holding Co Ltd (2629) operate in?
Mirxes Holding Co Ltd belongs to the Other sector and operates in the Biotechnology industry.
What is Mirxes Holding Co Ltd (2629) current stock price?
As of the latest data, Mirxes Holding Co Ltd stock price is HK$12.41, with a previous close of HK$12.41.
What is Mirxes Holding Co Ltd (2629) current market capitalization?
Mirxes Holding Co Ltd market cap is approximately 3.70 billion.
Does Mirxes Holding Co Ltd (2629) pay dividends?
No. Mirxes Holding Co Ltd does not pay a dividend.
What is Mirxes Holding Co Ltd (2629) beta (volatility) score?
Mirxes Holding Co Ltd has a beta of 0.433, indicating lower volatility than the overall market.